The headline reads as positive (92% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
Stocks › KYMR
Kymera Therapeutics, Inc. (KYMR) stock analysis
BUY 47% confidence · analysed Oct 29, 2026
On Oct 29, 2026, our model rated Kymera Therapeutics, Inc. (KYMR) BUY with 47% confidence at a price of $126.75. That means most of the technical, fundamental, money-flow and news signals point to upside.
Analysed price$126.75
Technical picture
The 14-day RSI is 69, showing healthy upward momentum without being stretched.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is only 0.1x its 20-day average; light trading makes the latest move less convincing.
Trend structure and money flow
Market structure: bullish structure intact, no fresh break.
The most recent swing high is $130.05 and the swing low is $99.52; traders often treat these as resistance and support.
Fundamentals
The company reports a profit margin of -285.3% and revenue growth of +466.4%.
In its latest quarter it earned $-0.62 per share, which beat the $-0.74 analysts expected, with revenue +466.4% year over year.
Wall Street's average rating is 1.4 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $139.83.
Trade plan from the model
The model's long / bullish plan uses an entry near $126.92, a target of $139.83 (+10.2%) and a stop-loss at $117.19 (-7.7%).
That is a reward-to-risk ratio of about 1.3 to 1: the potential gain is not much bigger than the loss, so the setup is marginal.
The plan has a time limit: reassess by Nov 19, 2026 whatever the price does.
Entry$126.92
Target$139.83
Stop-loss$117.19
Reassess byNov 19, 2026
Research notes
KYMR’s bull case centers on KT-621, its once-daily oral STAT6 degrader: positive Phase 1b atopic-dermatitis data, rapid BROADEN2 enrollment, and topline results expected by year-end 2026 could support Phase 3 development in 2027. The bear case is the company’s widening losses—Q3 net loss reached $132 million with no collaboration revenue—and the risk that disappointing or delayed KT-621 results undermine a high-spending, clinical-stage pipeline. The major recent catalyst is positive Phase 1 data for oral IRF5 degrader KT-579, showing at least 90% median IRF5 degradation and broad inflammatory biomarker inhibition; Kymera also said its $1.6 billion cash position should fund operations into 2029.
The model's one-paragraph read
Leans BUY — composite score +0.47 (BUY). Technicals: RSI 68.92, MACD bullish, price above SMA50. Fundamentals: margin -285.3%, revenue growth 466.4%. Financial results: YoY revenue +466.4%, last EPS surprise +16.2%. Smart Money Concepts: bullish structure intact, no fresh break. FinGPT news read: neutral. Internet research: KYMR’s **bull case** centers on KT-621, its once-daily oral STAT6 degrader: positive Phase 1b atopic-dermatitis data, rapid BROADEN2 enrollment, and topline results expected by year-end 2026 could support Phase 3 development in 2027. The **bear case** is the company’s widening losses—Q3 net loss reached $132 million with no collaboration revenue—and the risk that disappointing or delayed KT-621 results undermine a high-spending, clinical-stage pipeline. The major recent catalyst is positive Phase 1 data for oral IRF5 degrader KT-579, showing at least 90% median IRF5 degradation and broad inflammatory biomarker inhibition; Kymera also said its $1.6 billion cash position should fund operations into 2029. Suggested levels: entry $126.92, target $139.83, stop-loss $117.19, exit by 2026-11-19 (21-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for KYMR
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 29, 2026 | BUY | 47% | $126.75 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on KYMR
Oct 29, 2026 · Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
- Oct 29, 2026: Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial (GlobeNewswire)
Frequently asked questions
Is KYMR a buy right now?
As of Oct 29, 2026, our automated model rates Kymera Therapeutics, Inc. (KYMR) BUY with 47% confidence: most of the technical, fundamental, money-flow and news signals point to upside. This is a model output for education, not personal investment advice.
What is the price target for KYMR?
The model's most recent plan targets $139.83 with a stop-loss at $117.19, from an entry near $126.92.
What does a BUY rating mean?
A BUY rating means most of the technical, fundamental, money-flow and news signals point to upside.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.